Le Lézard
Classified in: Health
Subjects: CCA, FVT

Ionis to hold first quarter 2024 financial results webcast


Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time

CARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.

The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. ? [email protected] ? 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer ? [email protected] ? 760-603-4679

SOURCE Ionis Pharmaceuticals, Inc.


These press releases may also interest you

at 10:13
Leopoly Introduces LeoShape: Transforming Orthotics & Prosthetics with Cutting-Edge 3D design tech, Revolutionizing The Industry.
Leopoly, a leading innovator in 3D modeling and extended reality (XR) software solutions, unveils its new product line,LeoShape, marking a significant milestone in the orthotics and prosthetics (O&P) sector. Developed as a Smart CAD solution, this...

at 10:05
Pharmaceutical Strategies Group Announces Strategic Leadership Enhancements to Meet Growing Client Needs
Pharmaceutical Strategies Group ("PSG"), an EPIC company, has added two significant enhancements to its leadership team aimed at further empowering healthcare payers and driving innovation within the pharmacy benefits industry. The company welcomes...

at 10:05
OverT Bio Raises $16 Million, Tapping Innovative Reprogramming of Immune Cells to Deliver Next-Generation Therapies
OverT Bio, a data-driven company working to unlock the curative potential of cell therapies in solid tumors, announced today that it has raised $16 million in seed funding. The round was co-led by ARTIS Ventures and Wing VC, with participation from...

at 10:05
Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing...

at 10:05
BrainTale Accelerates Its International Expansion and Unveils Tier-one Collaborations to Improve Brain Care and Enable Precision Neurology
BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, unveils today a selection of leading research centers collaborations. For its partners, BrainTale offers innovative...

at 10:00
German car manufacturer visits HoneyNaps, a South Korean sleep tech company, to develop new automotive healthcare applications
Amid the rapid advancement in automobile healthcare and digital healthcare markets, global car manufacturers are racing to adopt cutting edge healthcare technologies for in-vehicle driver health monitoring....

More news about Health...


News published on and distributed by: